Baseline visit | |||||||
JDM A (n = 10) | JDM B (n = 13) | JDM C (n = 14) | p-value | JDM Total (n = 37)a | HC (n = 39)a | p-value | |
HPV 16, n (%) | 1 (10.0) | 6 (46.0) | 3 (21.0) | 0.142 | 10 (27.0) | 2 (5.0) | 0.012 |
HPV 18, n (%) | 1 (10.0) | 4 (31.0) | 4 (29.0) | 0.571 | 9 (24.0) | 1 (3.0) | 0.006 |
After the second qHPV vaccine dose | |||||||
JDM A (n = 10) | JDM B (n = 11) | JDM C (n = 15) | p-value | JDM Total (n = 36)b | HC (n = 14)c | p-value | |
HPV 16, n (%) | 10 (100) | 10 (91.0) | 14 (93.0) | 1.000 | 34 (94.0) | 14 (100) | 1.000 |
HPV 18, n (%) | 10 (100) | 10 (91.0) | 13 (87.0) | 0.770 | 33 (92.0) | 14 (100) | 0.265 |
After the thrid qHPV vaccine dose | |||||||
JDM A (n = 8) | JDM B (n = 11) | JDM C (n = 12) | p-value | JDM Total (n = 31)b | HC (n = 31)c | p-value | |
HPV 16, n (%) | 8 (100) | 11 (100) | 12 (100) | – | 31 (100) | 31 (100) | 1.000 |
HPV 18, n (%) | 8 (100) | 11 (100) | 11 (92.0) | 1.000 | 30 (97.0) | 31 (100) | 1.000 |
Six months after the third qHPV vaccine dose | |||||||
JDM A (n = 5) | JDM B (n = 7) | JDM C (n = 5) | p-value | JDM Total (n = 17)b | HC | p-value | |
HPV 16, n (%) | 5 (100) | 6 (86.0) | 5 (100) | 1.000 | 16 (94.0) | NA | NA |
HPV 18, n (%) | 5 (100) | 6 (86.0) | 5 (100) | 1.000 | 16 (94.0) | NA | NA |